ReportThe PASE questionnaire: Pilot-testing a Psoriatic Arthritis Screening and Evaluation tool
Section snippets
Instrument design
An initial question pool was generated from a review of the literature, patient data available from multi-center studies, informal open patient interviews, and expert opinion from rheumatologists and dermatologists as has been done previously using a Delphi method.16 Measurement goals were specified; an initial pool of 34 items was generated after a 1-round Delphi process involving institutional dermatologists and rheumatologists who were experts or had a special interest in psoriasis and PsA.
Results
Responses from a total of 69 patients who were administered the PASE questionnaire when presenting to the Center for Skin and Related Musculoskeletal Diseases were analyzed (Table I). All study participants had to have a diagnosis of psoriasis to be included in the study and be self-administered the PASE questionnaire at the time of visit to the clinic. The average age was 51 years, and 51% were female. The average age in the PsA group was 45 years; in the non-PsA group, the average age was 53
Discussion
The major goal of this study was to establish and pilot test a self-administered questionnaire to help dermatologists and other healthcare providers who treat psoriasis patients screen for PsA. The diagnosis of PsA using this questionnaire alone is not the goal of this work. The combined dermatology-rheumatology clinic and close working relationship between the two specialties served as an optimal test-bed for development of this tool. PASE is not designed or intended to substitute for a
References (18)
- et al.
The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach
J Am Acad Dermatol
(2006) - et al.
Psoriatic arthritis: prevalence, diagnosis, and review of therapy for the dermatologist
Dermatol Clin
(2004) - et al.
Psoriatic arthritis
Semin Arthritis Rheum
(1973) - et al.
Development of diagnostic criteria for psoriatic arthritis: methods and process
Curr Rheumatol Rep
(2004) - et al.
Psoriatic arthritis: performance of rheumatologists in daily practice
Ann Rheum Dis
(2002) - et al.
Psoriatic arthritis and psoriasis: need for a multidisciplinary approach
Semin Cutan Med Surg
(2005) Management of psoriatic arthritis: the therapeutic interface between rheumatology and dermatology
Curr Rheumatol Rep
(2006)Recent advances in the management of psoriatic arthritis
Curr Opin Rheumatol
(2004)- et al.
Diagnosis and management of psoriatic arthritis
Drugs
(2002)
Cited by (184)
Prevalence and demographic characteristics of psoriatic arthritis in Colombia: Data from the National Health Registry 2012–2018
2023, Revista Colombiana de ReumatologiaValidation of the Toronto Psoriatic Arthritis Screening 2 (TOPAS-2) questionnaire in an Argentinian population
2023, Revista Colombiana de ReumatologiaDermatologists’ Role in the Early Diagnosis of Psoriatic Arthritis: Expert Recommendations
2020, Actas Dermo-SifiliograficasImprove the diagnosis and management of psoriatic arthritis, from screening questionnaires to multidisciplinary care
2020, Revue du Rhumatisme MonographiesMeasuring Psoriasis Severity at Home
2024, Journal of Visualized Experiments
Supported by a grant from the Department of Dermatology, Brigham and Women's Hospital (to A. A. Q.).
Disclosure: Dr Qureshi is a consultant for and has spoken for Abbott, Amgen, and Genentech, and has had a limited consulting relationship with Centocor. Dr Mody is a speaker for Abbott, Amgen, and Genentech. Dr Husni is a consultant for Genentech and Amgen. Ms Meyer and Dr Cohen have no conflicts of interest to declare.